Icon

EPIDUO FORTE - (0.3%; 2.5%; Gel, Topical)

ADAPALENE; BENZOYL PEROXIDE Galderma
0.3%; 2.5%; Gel, Topical
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
None
Less Than 5
Less Than 5
Indicated for the topical treatment of acne vulgaris.
Yes
**** ****** ** ***. **** ***** * **** ** *** *** *********. ******* & **** *** ******* ** ****** ******* **** ****** *****. ******* (****) ***** **** ** **** ******* (*** **, ****); *******, ******* (*** **, ****) ** ******* *** *********. ** ****** **** ** *** ** ******* ** **** ****. *****, ********** *** ******* **** **** ****** *** *******, ***** *** ***** ** ********** *** *** *****. *****, ***** ****** ***** * **** ** *** *** *********.
EPIDUO FORTE Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9
**** ****** ******* ******* ******* ******* ******* ******* ******* ******* *******
******* ******* ******* ******* ******* ******* ******* ******* ******* *******
***** ****** ******* ******* *** ********* ******* *** ********* ******* *** ********* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** ****** *** \ *** *** **, **** ******* ******** ******** ** *** **, ****
******* ** \ ** **** **, **** ******* ******** ********
***** ****** ** \ ** ***** **, **** ******* ******** ********
  1. *** **, **** : **** ********* **** ** ************* **** ******* (*** **, ****); *******, ******* (*** **, ****) ** *******.
  2. *** **, **** : ******** **** **** ** ** ** ******** ******** ** *****.
  3. *** **, **** : ******* (****) ******** ******** ********* *** **** ** ************* **** ******* (*** **, ****); *******, ******* (*** **, ****) ** *******.
  4. *** **, **** : ******** ******* **** **** ******, ***** *** ***** ** ********** *** *** *****.
  5. *** **, **** : ******** **** ******** (****) ** ** ** ******** ******** ** *****.
  6. *** **, **** : ******** ******* **** *******, ***** *** ***** ** ********** *** *** *****.
  7. *** **, **** : ***** ******** ******** ***** *** **** ****** **** ****** '***, '***, '***, ***, '***, *** '***
  8. *** **, **** : ******** **** ***** *** ********** ****** **. '***, '***, '***, ***, '***, *** '***
  9. *** **, **** : ******** ******* **** ***** ** ******* *****.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.